Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + tenofovir disoproxil fumarate + granulocyte-macrophage colony-stimulating factor + hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Oral
01
Overview
This experimental quadruple combination therapy is designed to achieve a functional cure (HBsAg loss) in patients with chronic hepatitis B. The regimen combines the direct antiviral suppression of tenofovir disoproxil fumarate (a nucleotide analogue) with the immunomodulatory and antiviral effects of peginterferon alfa-2b. To further stimulate the host's immune system against the virus, granulocyte-macrophage colony-stimulating factor (GM-CSF) is utilized as an adjuvant alongside a therapeutic hepatitis B vaccine (HBsAg). This multi-pronged approach aims to break immune tolerance and induce a robust, virus-specific immune response. The therapy has been primarily investigated in pilot studies and investigator-initiated trials at The First Affiliated Hospital, College of Medicine, Zhejiang University.
- Other names
- Peg-IFNα-2b + TDF + GM-CSF + HBV vaccineQuadruple therapy for HBV
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on peginterferon alfa-2b + tenofovir disoproxil fumarate + granulocyte-macrophage colony-stimulating factor + hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + tenofovir disoproxil fumarate + granulocyte-macrophage colony-stimulating factor + hepatitis B vaccine.